MedTrace Logo

Pilot Study of Edaravone to Treat Acute Myocardial Infarction

NCT00265239 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-09-15

Study results available
· View outcomes & findings →

Summary

Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.

Conditions

Interventions

DRUG

edaravone

intravenous administration of 30mg Edaravone just before reperfusion therapy

Sponsors & Collaborators

  • Japan Heart Foundation

    collaborator OTHER

  • Kumamoto University

    lead OTHER

Principal Investigators

  • Hisao Ogawa, MD, PhD · Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Completion
2007-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265239 on ClinicalTrials.gov